CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Also, integrating DEGs in CD34+ blasts from CML patients treated with Imatinib (400 mg daily, 1 week) were also similarly enriched for proximal NCOR1 binding (22.2%) (83).